Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
61.60
-1.35 (-2.14%)
May 28, 2026, 10:10 AM HKT
Market Cap12.52B
Revenue (ttm)197.25M
Net Income-235.27M
EPS-1.35
Shares Out 198.89M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume47,100
Open63.90
Previous Close62.95
Day's Range61.60 - 63.90
52-Week Range44.72 - 97.50
Betan/a
AnalystsBuy
Price Target94.77 (+53.85%)
Earnings DateMay 29, 2026

About Nanjing Leads Biolabs

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma; LBL-007, a novel anti-LAG-3 antibody designed to restore T-cell activity; LBL-034, a novel GPRC5D-targeting T-cell engager for anti-tumor activity. In addition, it develops LeadsBody platform,... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 244
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9887
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements